VYNE News and Press, VYNE Therapeutics Inc Com From 01/24/21

These Biotech Penny Stocks Have Already Made Big Waves In 2021 But Can That Continue? If there’s one sector that’s been bullish for both penny stocks and blue-chips alike in 2021, it’s been biotech. Last year, we saw these stocks surge thanks to the onset of the...

VYNE Therapeutics has destroyed a lot of shareholder value since it came public in early 2016 as Menlo Therapeutics. The news flow seems a bit more positive since it combined with Foamix to form VYNE Therapeutics. We take an in depth look at this $2 biopharma concern in the paragr...

BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the execution of a contract with a major PBM for its novel AMZEEQ ® (minocycline) topical foam, 4% and ZILXI ® ...

BRIDGEWATER, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in two panel presentations at the LifeSci Partners 10th Annual H...

VYNE Therapeutics (VYNE) perks up 6% premarket on successful completion its End-of-Phase 2 Meeting with the FDA.The Company, in consultation with the FDA, has established the key elements of the Phase 3 program to support a New Drug Application ((NDA)) for FCD105 (3% minocyclin...

BRIDGEWATER, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) , a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today ...

BRIDGEWATER, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it has been selec...

BRIDGEWATER, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today a...

ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults ZILXI demonstrated a favorable safety and tolerability profile for up to 52 weeks of treatment Efficacy of ZILXI continued to dev...

BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Confere...